Results 211 to 220 of about 87,798 (246)
Monoclonal antibodies in myeloma. [PDF]
Clinical advances in hematology & oncology : H&O, 2015 The development of monoclonal antibodies (mAbs) for the treatment of disease goes back to the vision of Paul Ehrlich in the late 19th century; however, the first successful treatment with a mAb was not until 1982, in a lymphoma patient. In multiple myeloma, mAbs are a very recent and exciting addition to the therapeutic armamentarium. The incorporation
Sondergeld, P. +3 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Revue Francaise de Transfusion et Immuno-hématologie, 1988
The Rh antibodies were studied by manual serological techniques (see Daniels' report on Kell related antigens), using human red cells of common and rare Rh phenotypes in an attempt to identify their specificity and/or usefulness as reagents. The report is divided into 3 sections : section I anti-D antibodies, section II other Rh specifities, section ...
P, Tippett, C, Lomas
openaire +2 more sources
The Rh antibodies were studied by manual serological techniques (see Daniels' report on Kell related antigens), using human red cells of common and rare Rh phenotypes in an attempt to identify their specificity and/or usefulness as reagents. The report is divided into 3 sections : section I anti-D antibodies, section II other Rh specifities, section ...
P, Tippett, C, Lomas
openaire +2 more sources
Antibodies and Selection of Monoclonal Antibodies
2015Monoclonal antibodies are universal binding molecules with a high specificity for their target and are indispensable tools in research, diagnostics and therapy. The biotechnological generation of monoclonal antibodies was enabled by the hybridoma technology published in 1975 by Köhler and Milstein.
Katja, Hanack +2 more
openaire +2 more sources
Molecular and Cellular Biochemistry, 1984
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
S P, Cole +4 more
openaire +4 more sources
The technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described.
S P, Cole +4 more
openaire +4 more sources
Monoclonal antibodies and arthritis
Agents and Actions, 1990Monoclonal antibodies to certain cell surface constituents on lymphocytes, monocytes and macrophages have been administered to Lewis rats with developing, established or adoptively transferred arthritis, to determine any immunomodulatory properties.
M E, Billingham, C, Hicks, S, Carney
openaire +2 more sources
Current Opinion in Cardiology, 1996
Monoclonal antibody technology has become an important diagnostic and therapeutic tool in many areas of medicine, including the prevention and treatment of organ transplant rejection. The monoclonal antibody that has been most widely used clinically is OKT3, a murine monoclonal antibody directed against the CD3 receptor on the surface of human T cells.
openaire +2 more sources
Monoclonal antibody technology has become an important diagnostic and therapeutic tool in many areas of medicine, including the prevention and treatment of organ transplant rejection. The monoclonal antibody that has been most widely used clinically is OKT3, a murine monoclonal antibody directed against the CD3 receptor on the surface of human T cells.
openaire +2 more sources
Frontiers in Bioscience, 2006
The concept of targeted therapy was conceived through increased understanding of the biological pathways involved in the pathogenesis of cancer and subsequently identification of the most appropriate antigens to target. Monoclonal antibody therapy harnesses host defense mechanisms through activation of the antibody dependent cytotoxic pathway and ...
Deirdre, O'Mahony, Michael R, Bishop
openaire +2 more sources
The concept of targeted therapy was conceived through increased understanding of the biological pathways involved in the pathogenesis of cancer and subsequently identification of the most appropriate antigens to target. Monoclonal antibody therapy harnesses host defense mechanisms through activation of the antibody dependent cytotoxic pathway and ...
Deirdre, O'Mahony, Michael R, Bishop
openaire +2 more sources
Monoclonal Antibodies: A Review
Current Clinical Pharmacology, 2018Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb was the first FDA approved therapeutic MAb for the prevention of kidney transplant rejection.
Surjit, Singh +6 more
openaire +2 more sources
2009
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
Rheumatic Disease Clinics of North America, 1998
Animal models of human autoimmune disease suggest that it should be possible to reinduce self-tolerance in these conditions by the use of T-cell directed therapies, in particular with anti-CD4 monoclonal antibodies (CD4-mAb). Many studies have shown that CD4-mAb can prevent and in a treatment setting suppress activity of these disease models, including
openaire +2 more sources
Animal models of human autoimmune disease suggest that it should be possible to reinduce self-tolerance in these conditions by the use of T-cell directed therapies, in particular with anti-CD4 monoclonal antibodies (CD4-mAb). Many studies have shown that CD4-mAb can prevent and in a treatment setting suppress activity of these disease models, including
openaire +2 more sources